Show simple item record

dc.contributor.authorKeaney, Daniel
dc.contributor.authorWhelan, Shane
dc.contributor.authorFinn, Karen
dc.contributor.authorLucey, Brigid
dc.contributor.editorMartin-Loeches, Ignacio
dc.date.accessioned2021-06-03T10:18:49Z
dc.date.available2021-06-03T10:18:49Z
dc.date.copyright2021
dc.date.issued2021-05-25
dc.identifier.citationKeaney D, Whelan S, Finn K, Lucey B. Misdiagnosis of SARS-CoV-2: A Critical Review of the Influence of Sampling and Clinical Detection Methods. Medical Sciences. 2021; 9(2):36. https://doi.org/10.3390/medsci9020036en_US
dc.identifier.urihttp://research.thea.ie/handle/20.500.12065/3595
dc.description.abstractSARS-CoV-2 infection has generated the biggest pandemic since the influenza outbreak of 1918–1919. One clear difference between these pandemics has been the ability to test for the presence of the virus or for evidence of infection. This review examined the performance characteristics of sample types via PCR detection of the virus, of antibody testing, of rapid viral antigen detection kits and computerised tomography (CT) scanning. It was found that combined detection approaches, such as the incorporation of CT scans, may reduce the levels of false negatives obtained by PCR detection in both symptomatic and asymptomatic patients, while sputum and oral throat washing sample types should take precedence over swabbing when available. Rt-PCR assays for detection of the virus remain the gold-standard method for SARS-CoV-2 diagnosis and can be used effectively on pooled samples for widespread screening. The novel Oxford antibody assay was found to have the highest sensitivity and specificity of four currently available commercial antibody kits but should only be used during a specific timeframe post-symptom onset. Further research into transmission modes between symptomatic and asymptomatic patients is needed. Analysis of the performance characteristics of different sampling and detection methods for SARS-CoV-2 showed that timing of sampling and testing methods used can greatly influence the rate of false-positive and false-negative test results, thereby influencing viral spread.en_US
dc.formatapplication/pdfen_US
dc.language.isoengen_US
dc.publisherMDPI Journalsen_US
dc.relation.ispartofMedical Sciencesen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectRt-PCRen_US
dc.subjectsamplingen_US
dc.subjectdetection methodsen_US
dc.subjectantibody testsen_US
dc.subjectantigen testsen_US
dc.subjectsymptomaticen_US
dc.subjectasymptomaticen_US
dc.subjectdiagnosisen_US
dc.titleMisdiagnosis of SARS-CoV-2: A Critical Review of the Influence of Sampling and Clinical Detection Methodsen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.contributor.affiliationDepartment of Biological Sciences, Munster Technological University, Bishopstown, T12 P928 Cork, Irelanden_US
dc.contributor.affiliationDepartment of Biopharmaceutical and Medical Science, Galway-Mayo Institute of Technology, Old Dublin Road, H91 DCH9 Galway, Irelanden_US
dc.contributor.sponsorDaniel Keaney and Shane Whelan are in receipt of RISAM scholarships from Munster Technological University (RISAM_SW_2018; RISAM_DK_2018).en_US
dc.description.peerreviewyesen_US
dc.identifier.doi10.3390/medsci9020036en_US
dc.identifier.issue2en_US
dc.identifier.orcid0000-0003-2482-8331en_US
dc.identifier.orcid0000-0002-5631-9710en_US
dc.identifier.orcid0000-0002-0872-202Xen_US
dc.identifier.urlhttps://www.mdpi.com/2076-3271/9/2/36en_US
dc.identifier.volume9en_US
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessen_US
dc.subject.departmentDepartment of Biopharmaceutical and Medical Scienceen_US
dc.type.versioninfo:eu-repo/semantics/publishedVersionen_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International